Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,738 matching trials from the live ClinicalTrials.gov search.
Conditions
Post-Traumatic Stress Disorders
Interventions
individualized Transcranial Magnetic Stimulation
Device
Lead sponsor
72nd Medical Group, Tinker Air Force Base
Federal
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Not applicable Interventional Accepts healthy volunteers

Iron Supplementation and Side Effects

NCT04018300
Conditions
Iron Deficiency Anemia, Iron Overload
Interventions
Ferrous sulfate, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ames, Iowa
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Conditions
Asthma
Interventions
E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Jose, California • Stockton, California
Conditions
Posttraumatic Stress Disorder
Interventions
Prazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Ileal Pouch, Crohn Disease
Interventions
Mesenchymal stem cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Conditions
Spinal Cord Injury
Interventions
Tiotropium Bromide, Placebo
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity, Overweight, Healthy
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Allergy, Asthma
Interventions
Glycerinated German cockroach allergenic extract, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Conditions
Severe, Refractory Asthma, Airway Inflammation, Airflow Obstruction
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-668

NCT05727800
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
VX-668, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 76 Years
Enrollment
1,254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
177
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more
Completed Not applicable Interventional Accepts healthy volunteers

The Long-term Effects of Oceanix™ on Resistance Training Adaptations

NCT04136821
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Body Composition, Muscle Damage
Interventions
Oceanix, Resistance Training
Dietary Supplement · Other
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 2 Interventional Results available

Use of Donepezil for Treatment of Cocaine Dependence

NCT00467389
Conditions
Cocaine Abuse and Dependence
Interventions
Donepezil, 5 mg daily, Oral Placebo
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Multiple System Atrophy, Parkinson Disease
Interventions
UB-312 Injection, Placebo Injection
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

Efficacy of IV Acetaminophen for Pain Management

NCT02028715
Conditions
Post-operative Pain
Interventions
Placebo, IV acetaminophen
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Canton, Ohio
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Pillar Palatal Implant System, Sham system
Device
Lead sponsor
Medtronic Xomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • Berkeley, California • Denver, Colorado + 4 more
Terminated Phase 4 Interventional Results available

Pancreatic Enzyme Supplementation for Celiac Disease

NCT02475369
Conditions
Celiac Disease
Interventions
pancrelipase
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Kidney Diseases
Interventions
Control, Protein, Protein + Exercise
Dietary Supplement · Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
30 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Urbana, Illinois